Nuvation Bio Inc. Class A

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in Nuvation Bio Inc. Class A.

News

Owning 41% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB),

Simply Wall St Key Insights Institutions' substantial holdings in Nuvation Bio implies that they have significant influence over the...\n more…

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Business Wire Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder...\n more…

Nuvation Bio Inc. (NYSE:NUVB) Shares Sold by SG Americas Securities LLC

Ticker Report SG Americas Securities LLC reduced its position in Nuvation Bio Inc. (NYSE:NUVB - Free Report) by 37.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 31,916...\n more…

Nuvation Bio (NYSE:NUVB) Stock Rating Reaffirmed by Wedbush

Zolmax Wedbush restated their outperform rating on shares of Nuvation Bio (NYSE:NUVB - Free Report) in a research report report published on Thursday morning, RTT News reports. They currently have a $5.00...\n more…

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

SeekingAlpha Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024...\n more…

Q3 2024 Earnings Forecast for Nuvation Bio Inc. (NYSE:NUVB) Issued By Wedbush

Ticker Report Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Analysts at Wedbush cut their Q3 2024 earnings per share (EPS) estimates for Nuvation Bio in a note issued to investors on Monday, August 5th. Wedbush...\n more…